SUROTOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C77H101N17O26
Molecular Weight	1680.7241
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCC1=CC=C(C=C1)C(\C)=C\C(=O)N[C@@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](CC(=O)C5=C(N)C=CC=C5)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC4=O)[C@H](C)CC(O)=O

InChI

InChIKey=DYNMYYRPPFVAKR-CWXHRMTKSA-N

InChI=1S/C77H101N17O26/c1-6-7-8-14-41-20-22-42(23-21-41)37(2)25-58(98)86-49(27-43-33-81-47-18-12-10-15-44(43)47)71(113)89-50(29-57(80)97)72(114)91-53(32-64(107)108)73(115)94-66-40(5)120-77(119)54(28-56(96)45-16-9-11-17-46(45)79)92-76(118)65(38(3)26-61(101)102)93-74(116)55(36-95)87-60(100)34-82-68(110)51(30-62(103)104)88-67(109)39(4)84-70(112)52(31-63(105)106)90-69(111)48(19-13-24-78)85-59(99)35-83-75(66)117/h9-12,15-18,20-23,25,33,38-40,48-55,65-66,81,95H,6-8,13-14,19,24,26-32,34-36,78-79H2,1-5H3,(H2,80,97)(H,82,110)(H,83,117)(H,84,112)(H,85,99)(H,86,98)(H,87,100)(H,88,109)(H,89,113)(H,90,111)(H,91,114)(H,92,118)(H,93,116)(H,94,115)(H,101,102)(H,103,104)(H,105,106)(H,107,108)/b37-25+/t38-,39-,40-,48+,49+,50-,51+,52+,53+,54+,55-,65+,66+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C77H101N17O26
Molecular Weight	1680.7241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	5
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28347318 | https://www.ncbi.nlm.nih.gov/pubmed/28961905 | https://www.ncbi.nlm.nih.gov/pubmed/30307842

Surotomycin is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin. Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

500, 1000, 2000, 4000 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:14:11 GMT 2023` Edited by `admin` on `Fri Dec 15 16:14:11 GMT 2023`
Record UNII	ON0N776N05
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUROTOMYCIN

Official Name

English

surotomycin [INN]

Common Name

English

SUROTOMYCIN [USAN]

Common Name

English

CB-183,315

Code

English

CB-183315

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C258